4,349 results match your criteria Biology of Blood and Marrow Transplantation[Journal]


The Art of Transplantation: Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplant.

Biol Blood Marrow Transplant 2018 Dec 15. Epub 2018 Dec 15.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.067DOI Listing
December 2018

Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Non-Viremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

Biol Blood Marrow Transplant 2018 Dec 15. Epub 2018 Dec 15.

Department of Experimental Therapeutics, and. Electronic address:

Early cytomegalovirus (CMV) reactivation remains a significant cause of morbidity and mortality in allogeneic hematopoietic cell transplant (HCT) recipients. CMVPepVax is an investigational peptide vaccine designed to control CMV infection in HCT patients seropositive for CMV by stimulating the expansion of T cell subsets that target the CMV tegument protein pp65. In a randomized Phase 1b pilot trial (NCT01588015), two injections of CMVPepVax (at days 28 and 56 post-HCT) demonstrated safety, immunogenicity, increased relapse-free survival, and reduced CMV reactivation and usage of antivirals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.070DOI Listing
December 2018

Analysis of Single Nucleotide Polymorphisms in the Gamma Block of the Major Histocompatibility Complex in Association with Clinical Outcomes of Hematopoietic Cell Transplantation: A CIBMTR Study.

Biol Blood Marrow Transplant 2018 Dec 8. Epub 2018 Dec 8.

Cleveland Clinic Foundation, Cleveland, OH.

HLA haplotype mismatches have been associated with higher risk of acute graft versus host disease (aGVHD) in patients receiving HLA matched unrelated donor (URD) hematopoietic cell transplant (HCT) unrelated donors. The Gamma block (GB) is located in the central MHC region between beta and delta blocks (encoding C & B and DR & DQ antigens, respectively). GB contains many inflammatory and immune regulatory genes such as Bf, C2 and C4 genes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183080
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.12.008DOI Listing
December 2018
1 Read

The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma.

Biol Blood Marrow Transplant 2018 Dec 8. Epub 2018 Dec 8.

Loyola University Medical Center, Internal Medicine, 2160 S 1(st) Ave, IL, Maywood, Illinois 60153, United States.

Multiple myeloma (MM) is a malignant disorder of plasma cells primarily affecting elderly patients and is the second most commonly diagnosed hematological neoplasm. With the recent influx of effective new agents available including proteasome inhibitors, immunomodulators, targeted monoclonal antibodies, and now chimeric antigen receptor t-cell therapy (CAR-T), the treatment landscape is evolving rapidly. While the role of consolidative autologous stem cell transplantation (ASCT) in first remission is well established, in the relapsed setting following up front ASCT, the role of a second ASCT (SAT) following reinduction is less clear and understudied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.002DOI Listing
December 2018

Human rhinovirus infections in hematopoietic cell transplant recipients: risk score for progression to lower respiratory tract infection.

Biol Blood Marrow Transplant 2018 Dec 8. Epub 2018 Dec 8.

Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N Seattle, WA 98109. Electronic address:

Human rhinovirus lower respiratory tract infection is associated with mortality following hematopoietic cell transplantation; however, risk factors for lower respiratory tract infection are not well characterized. We sought to develop a risk score for progression to lower respiratory tract infection from upper respiratory tract infection in hematopoietic cell transplantation recipients. Risk factors for lower respiratory tract infection within 90 days were analyzed using Cox regression among hematopoietic cell transplantation recipients with rhinovirus upper respiratory tract infection between 1/2009-3/2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.005DOI Listing
December 2018

Allogeneic hematopoietic stem cell transplantation, especially haploidentical HSCT, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era.

Biol Blood Marrow Transplant 2018 Dec 8. Epub 2018 Dec 8.

Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China. Electronic address:

Background: The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly haploidentical (haplo)-HSCT, in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) in the tyrosine kinase inhibitor (TKI) era is unclear. This study aimed to identify prognostic factors and explore the role of haplo-HSCT in the treatment of Ph+ALL in the TKI era.

Methods: We analyzed clinical data of Ph+ALL patients aged 1-18 years who received imatinib added to intensive chemotherapy at the start of induction therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.007DOI Listing
December 2018
2 Reads

Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor/Recipient Pairs with Improved Transplant Outcome.

Biol Blood Marrow Transplant 2018 Dec 8. Epub 2018 Dec 8.

Diagnostic Laboratories and Blood Research Institute, BloodCenter of Wisconsin, part of Versiti, Milwaukee, WI. Electronic address:

HLA matching by allele-level genotyping is largely based on genetic similarity between a few exons which encode the antigen recognition domain (ARD) of the HLA protein. Next-generation sequencing (NGS) can identify HLA genetic polymorphisms in non-ARD encoding exons, introns, and untranslated regions, but the impact of these polymorphisms on hematopoietic cell transplant (HCT) outcomes is unclear. We performed NGS-based sequencing of eleven HLA loci on a well-characterized retrospective cohort of 166 unrelated donor/recipient HCT pairs. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183080
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.12.006DOI Listing
December 2018
2 Reads

Autologous Stem Cell Transplant for IgM Associated AL amyloidosis.

Biol Blood Marrow Transplant 2018 Dec 7. Epub 2018 Dec 7.

Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester. Electronic address:

IgM related AL amyloidosis is a rare disease with patients presenting with more renal and neurological involvement and less cardiac involvement compared to those with non-IgM related disease. We retrospectively reviewed 38 patients receiving autologous stem cell transplant (ASCT) for IgM related AL amyloidosis at the Mayo Clinic between May 1999 and June 2018. Median age was 61 years and 71% were male. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.003DOI Listing
December 2018

Reduced-toxicity myeloablative conditioning consisting of fludarabine/busulfan/low-dose TBI/G-CSF-combined cytarabine in single cord blood transplantation for elderly patients with non-remission myeloid malignancies.

Biol Blood Marrow Transplant 2018 Dec 7. Epub 2018 Dec 7.

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

The optimal intensity of a conditioning regimen might be dependent on not only age and comorbidities, but also disease activity and the type of graft source. We evaluated the outcome of unrelated single cord blood transplantation (CBT) using a conditioning regimen of fludarabine 180 mg/m, intravenous busulfan 9.6 mg/kg, 4 Gy total body irradiation, granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine (Ara-C) (12 g/m) in 23 elderly patients (median, 64 years) with non-remission myeloid malignancies between 2013 and 2018 in our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.004DOI Listing
December 2018

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Biol Blood Marrow Transplant 2018 Dec 3. Epub 2018 Dec 3.

Department of Ophthalmology, Hospital Universitario Puerta de Hierro, Madrid, Spain.

Non-graft-versus-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.033DOI Listing
December 2018
8 Reads

Pulmonary impairment following respiratory viral infections is associated with high mortality in allogeneic hematopoietic cell transplant recipients.

Biol Blood Marrow Transplant 2018 Dec 3. Epub 2018 Dec 3.

Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Introduction: Pulmonary impairment predicts increased mortality in many settings, and respiratory viral infection (RVI) causes considerable morbidity and mortality in allogeneic hematopoietic cell transplant recipients (allo-HCT). We hypothesized that pulmonary impairment following respiratory viral infection, defined as a decline of forced expiratory volume in 1 second values by ≥10%, may identify allo-HCT recipients at high risk for mortality.

Methods: We studied all allo-HCT recipients at our institution who had RVI with respiratory syncytial virus, parainfluenza virus, or influenza from 2004-2013 and had pre-RVI and post-RVI pulmonary function tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.022DOI Listing
December 2018
2 Reads

Fludarabine/melphalan 100 mg/m Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.

Biol Blood Marrow Transplant 2018 Nov 30. Epub 2018 Nov 30.

Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Our previous research indicated that a reduced-intensity conditioning regimen (fludarabine and melphalan at 100 mg/m) was useful in allogeneic hematopoietic cell transplantation (HCT) for patients with lymphoma. This retrospective study evaluated the reduced-intensity conditioning regimen in allogeneic HCT for adult patients with hemophagocytic lymphohistiocytosis (HLH). Sixteen patients with HLH were evaluated, including 6 patients who were enrolled in a prospective clinical trial (NCT00772811) and 10 patients who received the same conditioning regimen (fludarabine at 30 mg/m/day on days -6 to -2 and melphalan at 100 mg/m on day -2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.032DOI Listing
November 2018
3 Reads

FLT3-ITD and CEBPA mutations predict prognosis in acute myeloid leukemia irrespective of hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant 2018 Nov 29. Epub 2018 Nov 29.

Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. Electronic address:

Cytogenetic and genetic changes have prognostic significance in acute myeloid leukemia (AML). In our study, we compared the cytogenetic changes and gene mutations (NPM1, CEBPA, DNMT3A, FLT3-ITD, FLT3-TKD and C-KIT) with clinical outcome in 1132 AML patients enrolled at our center over 10 years. A total of 977 patients provided gene mutation data: there were subsets of patients who exhibited mutations in NPM1 (17. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.031DOI Listing
November 2018

Flt3L treatment of bone marrow donors increases graft plasmacytoid dendritic cell content and improves allogeneic transplant outcomes.

Biol Blood Marrow Transplant 2018 Nov 29. Epub 2018 Nov 29.

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA. Electronic address:

Higher numbers of donor plasmacytoid dendritic cells (pDC) increased survival and reduced graft-versus-host disease (GvHD) in human recipients of unrelated donor bone marrow (BM), but not G-CSF peripheral blood grafts. In murine models, we have shown that donor BM pDC increase survival and decrease GvHD compared to G-CSF-mobilized pDC. To increase the content of pDC in BM grafts we studied the effect of FMS-like tyrosine kinase 3 ligand (Flt3L) treatment of murine BM donors on transplant outcomes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183077
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.029DOI Listing
November 2018
1 Read

Clinical and economic impact of the cytomegalovirus infection among children undergoing allogeneic hematopoietic cell transplantation.

Biol Blood Marrow Transplant 2018 Nov 28. Epub 2018 Nov 28.

Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, Columbia University Medical Center, New York, NY. Electronic address:

Literature on the impact of cytomegalovirus (CMV)-related hospitalization in allogeneic hematopoietic cell transplant (alloHCT) pediatric patients is limited. The aim of this study was to determine utilization and outcomes of CMV-related hospitalization in alloHCT patients using a single-center clinical database. This was a retrospective study of 240 children ages 3 months to 21 years old who were transplanted between 2005 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.028DOI Listing
November 2018

Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.

Biol Blood Marrow Transplant 2018 Nov 27. Epub 2018 Nov 27.

Clinical Research Division, Fred Hutchinson Cancer Research Center; Seattle, WA; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine; Seattle, WA. Electronic address:

The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) was developed and validated to weigh the burden of pretransplant comorbidities and estimate their impact on post-transplant risks of non-relapse mortality (NRM). Recently, the HCT-CI was augmented by the addition of both age and values of three markers namely, ferritin, albumin, and platelet count. The HCT-CI research so far has been almost exclusively limited to recipients of allogeneic HCT from human leucocyte antigen (HLA)-matched grafts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.030DOI Listing
November 2018

Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword.

Biol Blood Marrow Transplant 2018 Nov 27. Epub 2018 Nov 27.

Department of Leukemia, University of Texas, MD Anderson Cancer Center. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.026DOI Listing
November 2018

Haploidentical bone marrow transplant with post-transplant cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative.

Biol Blood Marrow Transplant 2018 Nov 27. Epub 2018 Nov 27.

Department of Medicine, Division of Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address:

Curative therapy for individuals with severe sickle cell disease (SCD) who lack an HLA-identical sibling donor has been frustratingly elusive. With the goal of improving engraftment while minimizing transplant related morbidity, a multi-institution learning collaborative was developed in 2013, in the context of a phase II clinical trial of a non-myeloablative, related HLA-haploidentical bone marrow transplant (haplo-BMT), with post-transplant cyclophosphamide. All eligible participants had HbSS, 89% (16/18) had an identifiable donor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.027DOI Listing
November 2018
1 Read

Patient-Reported Outcomes with Chimeric Antigen Receptor-T Cell Therapy: Challenges and Opportunities.

Biol Blood Marrow Transplant 2018 Nov 28. Epub 2018 Nov 28.

Cleveland Clinic, Cleveland, Ohio, USA.

Patient-reported outcomes (PROs) are an important tool to assess the impact of a new therapy on symptom burden and health-related quality of life (HRQoL). Chimeric Antigen Receptor-T (CAR-T) cell therapies have been approved for use in relapsed or refractory leukemia and lymphoma based on promising efficacy in clinical trials. However, there is a lack of data on patient-reported toxicity and impact on HRQoL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.025DOI Listing
November 2018

Occurrence and Severity of DLI associated Chronic GVHD Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2018 Nov 25. Epub 2018 Nov 25.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China. Electronic address:

The aim of this study was to investigate the occurrence and severity of chemotherapy plus donor lymphocyte infusion (Chemo-DLI) associated chronic graft-versus-host disease (cGVHD) in a consecutive cohort of patients with acute leukemia who experienced relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT; n = 104). The 5-year cumulative incidence of complete remission (CR) after Chemo-DLI was 81.0% (95% CI, 73. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.024DOI Listing
November 2018
3 Reads

Reduction in Mortality after Umbilical Cord Blood Transplantation in Children over a 20-Year Period (1995-2014).

Biol Blood Marrow Transplant 2018 Nov 24. Epub 2018 Nov 24.

Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, NC. Electronic address:

Background: Infections and graft-versus-host disease have historically resulted in high mortality among children undergoing umbilical cord blood transplantation (UCBT). However, recent advances in clinical practice have likely improved outcomes of these patients.

Methods: We conducted a retrospective cohort study of children (<18 years of age) undergoing UCBT at Duke University between January 1, 1995 and December 31, 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.018DOI Listing
November 2018
1 Read

A 4 or 5 Deauville score assessed by (18)F-FDG-PET CT early post-allotransplant is highly predictive of relapse in lymphoma patients.

Biol Blood Marrow Transplant 2018 Nov 24. Epub 2018 Nov 24.

Hematology Department, CHU, Nantes, France; Nantes-Angers Cancer Research Center (CRCINA), University of Nantes, Inserm UMR1232, 8 quai Moncousu, 44007 Nantes, France. Electronic address:

The impact of early Fluorine-18 Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) status on survival after allogeneic transplantation for lymphoma is poorly reported.This retrospective study included all adult Hodgkin (HL) or non-Hodgkin (NHL) lymphoma patients (>18 years old) who benefited from FDG PET-CT before (within 1 month) and/or early (+3 months and within +6-9 months) after Allo-SCT in our institution between 2005 and 2015 and who were still without documented progression nor relapse at the time of the FDG PET-CT. All FDG PET-CT were reviewed by a nuclear medicine expert in hematology and restaged according to the Deauville Scale. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.019DOI Listing
November 2018
1 Read

Peripheral Immunotype Correlates with Minimal Residual Disease Status and is Modulated by Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.

Biol Blood Marrow Transplant 2018 Nov 24. Epub 2018 Nov 24.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC. Electronic address:

There are data to indicate reversal of immune dysfunction with active treatment, however, the precise contribution of specific immune effector and immune suppressor components to achievement of minimal residual disease (MRD) state and IMiD-mediated immunomodulatory effects in multiple myeloma (MM) patients remains poorly understood. In this prospective proof-of-principle study we sought to determine the dynamic alterations in NK, NKT and T cell, including maturation and activating/inhibitory repertoire associated with MRD versus MRD status post autologous stem cell transplantation (ASCT) and during lenalidomide based maintenance therapy. Of the 46 MM patients enrolled, 36 had bone marrow MRD assessment 60+ days post-ASCT, 30 had longitudinal blood immunotyping during maintenance (pre-therapy, after cycles 1,3, and 6), and 20 had both MRD assessment and longitudinal immunotyping. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183074
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.015DOI Listing
November 2018
3 Reads

Effects of low-dose glucocorticoid prophylaxis on chronic GVHD and GVHD-free, relapse-free survival after haploidentical transplantation: long-term follow-up of a controlled, randomized open-label trial.

Biol Blood Marrow Transplant 2018 Nov 24. Epub 2018 Nov 24.

Peking University People's Hospital & Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 South Street of Xizhimen, Xicheng District, Beijing 100044, P.R.C; Peking-Tsinghua Center for Life Sciences, Beijing 100871, China. Electronic address:

This long-term follow-up study evaluated the effects of corticosteroid prophylaxis on GVHD-free, relapse-free survival (GRFS) based on a controlled open-label randomized trial in which 228 allotransplant recipients were categorized as low-risk (N = 83, group A) or high-risk; patients at high-risk were randomly assigned to receive (N = 72, group B) or not receive (N = 73, group C) low-dose methylprednisolone prophylaxis. The cumulative incidences of chronic GVHD, relapse, NRM, LFS, OS, and GRFS were 60%, 19%, 16%, 68%, 73%, and 46%, respectively, in the total cases. Compared with the patients in group C, the cases in group B experienced a lower cumulative incidence of moderate to severe chronic GVHD (42% vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.020DOI Listing
November 2018
1 Read

Fluoroquinolone prophylaxis is highly effective for the prevention of central line-associated bloodstream infections in autologous stem cell transplant patients.

Biol Blood Marrow Transplant 2018 Nov 24. Epub 2018 Nov 24.

Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA; Department of Healthcare Epidemiology, Infection Prevention and Control, University of Pennsylvania, Philadelphia, PA; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Objectives: Patients undergoing stem cell transplant (SCT) for the treatment of hematologic malignancy are at increased risk for central line-associated bloodstream infections (CLABSIs). The use of prophylactic antibiotics to prevent CLABSIs in the setting of autologous SCT is of unclear benefit. We aimed to evaluate the impact of levofloxacin prophylaxis on reducing CLABSIs in this high-risk population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.023DOI Listing
November 2018
1 Read

Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Biol Blood Marrow Transplant 2018 Nov 24. Epub 2018 Nov 24.

Department of Ophthalmology, University Clinical Hospital Zagreb, Zagreb, Croatia.

Ocular graft-versus-host disease (GVHD) occurs in more than half of patients who develop chronic GVHD after allogeneic hematopoietic cell transplantation (HCT), causing prolonged morbidity which affects activities of daily living and quality of life. Here we provide an expert review of ocular GVHD in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Recent updates in ocular GVHD, regarding pathophysiology, preclinical models, risk factors, prevention, screening, diagnosis, response criteria, evaluation measures, and treatment are discussed in this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.021DOI Listing
November 2018
1 Read

Cytomegalovirus (CMV) infection in allogeneic HCT managed by the preemptive approach: Estimating the impact on health care resource utilization and outcomes.

Biol Blood Marrow Transplant 2018 Nov 23. Epub 2018 Nov 23.

Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

Background: We quantified CMV antiviral use and hospital length of stay (LOS) associated with CMV infection in a contemporary cohort of conventional (CONV) and CD34-selected (T-cell depleted) HCT recipients managed by preemptive therapy (PET) in a single US center.

Methods: Adults who received first allogeneic HCT at MSKCC from June 2010 through December 2014 were analyzed. Days on PET, number and LOS of readmissions by day 180 post HCT were summarized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.012DOI Listing
November 2018

The Optimal Killer Cell Immunoglobulin-Like Receptor Donor-We Can Recognize, but Can We Search?

Biol Blood Marrow Transplant 2018 Nov 22. Epub 2018 Nov 22.

Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.010DOI Listing
November 2018
2 Reads

Addendum to: Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency Using Post-Transplantation Cyclophosphamide.

Biol Blood Marrow Transplant 2018 Nov 22. Epub 2018 Nov 22.

Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.014DOI Listing
November 2018

ETANERCEPT AS TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE IN PEDIATRIC PATIENTS.

Biol Blood Marrow Transplant 2018 Nov 21. Epub 2018 Nov 21.

Hematopoietic Stem Cell Transplant Unit; IRCSS, Istituto G. Gaslini, Genova.

Introduction: Corticosteroids are the standard of care for first line treatment of patients who develop grades II-IV of acute Graft-versus-Host Disease (a-GvHD), but the optimal second-line treatment has not been determined yet. We prospectively evaluated the use of anti-TNFα monoclonal antibody Etanercept (ET) as second line treatment in children with steroid-refractory a-GvHD.

Materials And Methods: Twenty-five children with either malignant or non malignant diseases experiencing grade II-IV steroid-refractory (SR)-a-GvHD received ET as second line treatment. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183075
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.017DOI Listing
November 2018
4 Reads

Choosing a Reduced Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-analysis.

Biol Blood Marrow Transplant 2018 Nov 21. Epub 2018 Nov 21.

Mayo Clinic, Phoenix, AZ.

Fludarabine with busulfan (FB) or melphalan (FM) are two more commonly used reduced intensity conditioning regimens for allogeneic stem cell transplantation (HCT).We present a systematic review and meta-analysis of studies comparing these two RIC regimens. We searched electronic databases from inception through November 1, 2017 for literature search to identify relevant studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.016DOI Listing
November 2018
3 Reads
3.404 Impact Factor

Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory GI Acute GvHD: A Retrospective Record Review.

Biol Blood Marrow Transplant 2018 Nov 20. Epub 2018 Nov 20.

Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.

Allogeneic hematopoietic cell transplantation can be curative in patients with hematological malignancies but carries a significant risk of graft-versus-host disease (GvHD). There are no standard treatments for steroid-refractory (SR) gastrointestinal (GI) acute GvHD (aGvHD). This multicenter, international, retrospective medical record review aimed to evaluate the off-label use of vedolizumab, a gut-selective immunomodulator, for treatment of SR GI aGvHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.013DOI Listing
November 2018
5 Reads

Allogeneic Stem Cell Transplantation after Fanconi Anemia Conditioning in Children with Ataxia-Telangiectasia Results in Stable T Cell Engraftment and Lack of Infections despite Mixed Chimerism.

Biol Blood Marrow Transplant 2018 Nov 7;24(11):2245-2249. Epub 2018 Jul 7.

Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland.

Ataxia-telangiectasia (A-T) syndrome is an autosomal recessive chromosomal breakage syndrome caused by mutation of the ataxia-telangiectasia mutated gene manifested by progressive neurodegeneration, telangiectasias of sclera and skin, immune deficiency with sinopulmonary infections, and increased incidence of lymphoid malignancies and solid tumors. Three children with A-T underwent allogeneic stem cell transplantation (SCT) using protocols for Fanconi anemia. All 3 patients were engrafted with a mixed donor-recipient chimerism, but the full donor engraftment was observed in the T lymphocyte compartment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.07.001DOI Listing
November 2018
8 Reads

Long-Term Follow-Up of Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.

Biol Blood Marrow Transplant 2018 Nov 3;24(11):2211-2215. Epub 2018 Jul 3.

Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address:

Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) can provide prolonged remissions in patients with advanced B cell lymphoma (B-NHL) via the graft-versus-lymphoma effect, although inferior results are seen in patients with chemoresistant, bulky, or aggressive disease. Radioimmunotherapy can safely induce responses in B-NHL with minimal nonhematologic toxicity. Initial results of Y-ibritumomab tiuxetan-based allografting demonstrated early safety and disease control in nonremission patients but with short follow-up. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183038
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.06.033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251312PMC
November 2018
2 Reads

Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease.

Biol Blood Marrow Transplant 2018 Nov 7;24(11):2190-2196. Epub 2018 Jul 7.

Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

Post-transplant biomarkers of acute graft-versus-host disease (aGVHD) and nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (allo-HCT) have been extensively studied. However, pretransplant biomarkers may provide a greater window of opportunity to intervene. We measured serum biomarkers of various aspects of gut barrier physiology before HCT (median, day -7) and 7 and 28 days post-HCT in 95 consecutive allo-HCT recipients enrolled in an open-label biorepository protocol. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183038
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.06.036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251308PMC
November 2018
4 Reads

The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma.

Biol Blood Marrow Transplant 2018 Nov 16. Epub 2018 Nov 16.

Division of Hematology/Oncology, Department of Medicine, University of Alabama Birmingham, Birmingham, Alabama.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183071
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.009DOI Listing
November 2018
2 Reads

Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2018 Nov 15. Epub 2018 Nov 15.

Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Joan and Sanford Weill Cornell Medical College, New York, New York. Electronic address:

In recent years, vancomycin-resistant Enterococcus (VRE) colonization is being increasingly encountered in transplant recipients, and VRE has become one of the leading causes of bacteremia early after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Data are sparse on the effect of empiric VRE therapy for febrile, neutropenic allo-HSCT recipients colonized with VRE. All allo-HSCT recipients aged ≥18 years who developed VRE bacteremia (VREB) between 2005 and 2014 were identified and categorized as to whether they received empiric or directed VRE therapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183071
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.008DOI Listing
November 2018
11 Reads

Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis.

Biol Blood Marrow Transplant 2018 Nov 14. Epub 2018 Nov 14.

Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, Canada; Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, Canada. Electronic address:

Previous studies have reported single B cell-related chronic graft-versus-host disease diagnostic (cGVHD) biomarkers, such as B cell-activating factor (BAFF), CD21, and immature B cells, but research on the performance of biomarker combinations and the covariate effect of steroids is lacking. The primary objective of this study was to determine the most accurate combination of B cell populations using cell surface staining flow cytometry in an independent cohort of patients with cGVHD. Secondary objectives included assessing the effect of corticosteroid use at sample collection on the makeup and accuracy of the diagnostic panel and identifying the mechanism underlying low surface expression of BAFF receptor (BAFF-R) on B cells in cGVHD. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183070
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.007DOI Listing
November 2018
3 Reads

Microbes and Their Metabolites Correlate with Hematopoietic Stem Cell Transplantation Outcomes?

Biol Blood Marrow Transplant 2018 Dec 12;24(12):e7-e8. Epub 2018 Nov 12.

Blood and Marrow Transplant Program, Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.006DOI Listing
December 2018

Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2018 Nov 10. Epub 2018 Nov 10.

Adult Bone Marrow Transplant Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Data are limited on whether to adjust high-dose chemotherapy before autologous hematopoietic cell transplant (autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients, defined as body mass index (BMI) ≥ 30 kg/m. Dose adjustment was defined as a reduction in standard dosing ≥ 20%, based on ideal, reported dosing and actual weights. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183069
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.005DOI Listing
November 2018
7 Reads
3.404 Impact Factor

Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Biol Blood Marrow Transplant 2018 Nov 10. Epub 2018 Nov 10.

Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota; National Marrow Donor Program/Be the Match, Minneapolis, Minnesota.

The development of reduced-intensity approaches for allogeneic hematopoietic cell transplantation has resulted in growing numbers of older related donors (RDs) of peripheral blood stem cells (PBSCs). The effects of age on donation efficacy, toxicity, and long-term recovery in RDs are poorly understood. To address this we analyzed hematologic variables, pain, donation-related symptoms, and recovery in 1211 PBSC RDs aged 18 to 79 enrolled in the Related Donor Safety Study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.11.004DOI Listing
November 2018
2 Reads

Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.

Biol Blood Marrow Transplant 2018 Nov 10. Epub 2018 Nov 10.

Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.

Conventional cytogenetic analyses and fluorescent in situ hybridization (FISH) are helpful for stratifying patients with multiple myeloma (MM) into high-risk [t(4;14), t(14;16), and/or del 17p] and standard-risk [t(11;14)] categories. However, the prognosis of patients with MM treated with autologous stem cell transplantation (ASCT) stratified according to these categories remains unclear. This retrospective observational study analyzed 97 patients with MM who received a single, planned ASCT after treatment with 200 mg/m melphalan between 2001 and 2011. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183069
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.003DOI Listing
November 2018
6 Reads

Impact of the Use and Type of Antibiotics on Acute Graft-versus-Host Disease.

Biol Blood Marrow Transplant 2018 Nov 3;24(11):2178-2183. Epub 2018 Jul 3.

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

The intestinal microbiota plays an important role in the pathogenesis of acute graft-versus-host disease (aGVHD). During the course of hematopoietic stem cell transplantation (HSCT), the intestinal microbiota is influenced by the use of broad-spectrum antibiotics. However, the impact of the use and type of antibiotics on the microbiota composition and, subsequently, the onset of aGVHD remain poorly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.06.031DOI Listing
November 2018
1 Read

Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.

Biol Blood Marrow Transplant 2018 Nov 9. Epub 2018 Nov 9.

Division of Hematology/Oncology, Department of Medicine. Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY. Electronic address:

Adoptive immunotherapy has shown efficacy in patients with relapsed/refractory acute myelogenous leukemia (AML). We conducted a prospective evaluation of cord blood (CB)-based adoptive cell therapy following salvage chemotherapy in patients with AML or myelodysplastic syndrome (MDS) and describe the safety and early outcomes of this approach. To enhance the antileukemic effect, we selected CB units (CBUs) with a shared inherited paternal antigen (IPA) and/or noninherited maternal antigen (NIMA) match with the recipients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183069
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.002DOI Listing
November 2018
3 Reads

Role of Regulatory T Cells in Noninherited Maternal Antigen-Related Tolerance in Cord Blood: An in Vitro Study.

Biol Blood Marrow Transplant 2018 Nov 6. Epub 2018 Nov 6.

Department of Pathology, The University of Hong Kong, Hong Kong.

Cord blood (CB) is an alternative stem cell source for allogeneic hematopoietic stem cell transplantation (HSCT). The unique advantages of using CB as a stem cell source are a degree of permissibility for HLA mismatch, rapid availability, and relatively risk-free cell collection. Because HLA is highly polymorphic and population-specific, optimal HLA-matched unrelated donors or cord blood units (CBUs) might not be available. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183069
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.10.021DOI Listing
November 2018
8 Reads

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Biol Blood Marrow Transplant 2018 Nov 5. Epub 2018 Nov 5.

The Transplant & Cellular Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183069
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.001DOI Listing
November 2018
5 Reads

Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2018 Nov 5. Epub 2018 Nov 5.

Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.

Disruption of the intestinal microbiome early after allogeneic hematopoietic cell transplantation (allo-HCT) has been linked to adverse outcomes in transplant recipients. To date, whether microbiome-directed interventions will be able to impact important clinical endpoints remains unknown. Fecal microbiota transplantation (FMT) is a compelling intervention to restore healthy diversity to the intestinal microenvironment after allo-HCT, but currently has no established role in transplant recipients. Read More

View Article

Download full-text PDF

Source
https://www.sciencedirect.com/science/article/pii/S108387911
Web Search
http://www.bbmt.org/article/S1083-8791(17)30960-6/abstract
Web Search
https://linkinghub.elsevier.com/retrieve/pii/S10838791183069
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.10.022DOI Listing
November 2018
6 Reads

Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant 2018 Nov 5. Epub 2018 Nov 5.

Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.

This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57 years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183065
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.10.017DOI Listing
November 2018
4 Reads

Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Biol Blood Marrow Transplant 2018 Nov 3. Epub 2018 Nov 3.

Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands; Radboud Institute of Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address:

Effective therapies for treating patients with steroid-refractory acute graft-versus-host-disease (SR-aGVHD), particularly strategies that reduce the duration of immunosuppression following remission, are urgently needed. The investigated immunotoxin combination consists of a mixture of anti-CD3 and anti-CD7 antibodies separately conjugated to recombinant ricin A (CD3/CD7-IT), which induces in vivo depletion of T cells and natural killer (NK) cells and suppresses T cell receptor activation. We conducted a phase I/II trial to examine the safety and efficacy of CD3/CD7-IT in 20 patients with SR-aGVHD; 17 of these patients (85%) had severe SR-aGVHD, and all 20 patients had visceral organ involvement, including 18 (90%) with gastrointestinal (GI) involvement and 5 (25%) with liver involvement. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183069
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.10.020DOI Listing
November 2018
8 Reads

Single-Unit versus Double-Unit Umbilical Cord Blood Transplantation in Children and Young Adults with Residual Leukemic Disease.

Biol Blood Marrow Transplant 2018 Oct 29. Epub 2018 Oct 29.

Department of Pediatric Hematology-Oncology, APHM, Timone Hospital, Aix-Marseille University, Marseille, France; Department of Public Health -EA 3279 Research Unit, Marseille University Hospital, Aix-Marseille University, Marseille, France. Electronic address:

We previously reported in a French prospective randomized study that transplantation of 2 unrelated cord blood (UCB) units instead of 1 unit does not decrease the risk of transplantation failure but may enhance alloreactivity. Here we evaluated the influence of pretransplantation minimal residual disease (MRD) on leukemia relapse and survival after single- versus double-UCB transplantation (UCBT). Among 137 children and young adults who underwent UCBT in this randomized study, 115 had available data on MRD assessment done immediately before initiation of the pretransplantation conditioning regimen. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183064
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.10.016DOI Listing
October 2018
7 Reads